Today: 7 February 2026
Subscribe
Browse Category

Healthcare News 21 January 2026 - 28 January 2026

CVS stock price dives 14% after CMS Medicare Advantage rate proposal; what investors watch next

CVS stock price dives 14% after CMS Medicare Advantage rate proposal; what investors watch next

CVS Health shares dropped about 14% to $72 in after-hours trading Tuesday after a proposed 2027 Medicare Advantage payment update signaled minimal rate increases. The Centers for Medicare & Medicaid Services projected a 0.09% average hike, sparking warnings from insurers about possible benefit cuts. UnitedHealth and Humana shares also fell sharply. CVS reports earnings Feb. 10; CMS’s final decision is due in April.
28 January 2026
····
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
······
Wall Street futures rise ahead of Fed decision as Medicare rate plan hits insurers, earnings roll in

Wall Street futures rise ahead of Fed decision as Medicare rate plan hits insurers, earnings roll in

S&P 500 and Nasdaq futures rose early Tuesday, while Dow futures slipped, weighed by UnitedHealth after Washington proposed keeping Medicare Advantage payments nearly flat for 2027. Insurers fell in premarket trading. Investors awaited earnings reports and the Federal Reserve’s policy decision due Wednesday. Salesforce shares gained on news of a $5.6 billion U.S. Army contract.
27 January 2026
·····
Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

New York, January 26, 2026, 14:55 EST — Regular session Shares of Boston Scientific Corp climbed 1.7% to $94.12 Monday afternoon, gaining $1.61 since Friday’s close. The stock fluctuated between $92.03 and $94.24, with roughly 5.4 million shares traded by mid-afternoon. Boston Scientific is gearing up to release its fourth-quarter and full-year 2025 results on Feb. 4. Investors will be watching closely for updates on procedure demand and pricing trends. CEO Mike Mahoney and CFO Jon Monson are scheduled to hold a conference call at 8 a.m. ET that day. (Boston Scientific) The deal lands amid ongoing debate over Boston
26 January 2026
·····
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

New York, Jan 25, 2026, 13:19 ET — Market closed Healthcare stocks finished last week lower, with XLV — the ETF tracking major U.S. healthcare companies — slipping 0.5% by Friday’s close. Eli Lilly weighed on the sector, though some of the bigger names in the index managed to hold up. The drop followed a choppy week for the broader U.S. market, rattled by earnings reports and geopolitical tensions. Investors were quick to unwind crowded bets. “We’re feeling pretty good, but mindful we might have some significant twists and turns,” said Jason Blackwell, chief investment strategist at Focus Partners Wealth.
25 January 2026
········
Abbott stock price: ABT heads into Monday after a two-day slide on nutrition worries

Abbott stock price: ABT heads into Monday after a two-day slide on nutrition worries

New York, January 24, 2026, 17:34 EST — Market closed Abbott Laboratories shares ended Friday at $107.42, slipping 1.1% after tumbling nearly 10% the previous day. Investors are reacting to a quarterly sales shortfall and a weaker 2026 forecast. When trading resumes Monday, the nutrition segment remains the primary concern for many analysts. (Investing.com) Abbott reported a 4.4% rise in fourth-quarter sales, reaching $11.46 billion. Organic growth, excluding currency effects, was 3.0%. The company projects organic sales growth between 6.5% and 7.5% for 2026, with adjusted earnings expected between $5.55 and $5.80 per share. For the first quarter, adjusted EPS
25 January 2026
·····
Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

New York, Jan 24, 2026, 13:07 EST — Market closed. The Health Care Select Sector SPDR Fund (XLV) dropped 0.51% to close at $157.48 on Friday. The S&P 500 Health Care index also slipped, down 0.56% by the closing bell. (Investing.com) This week matters because politics, payment rules, and earnings collide. The biggest players might act like defensives—until a reimbursement change or a Washington headline shifts the calculus. Investors seem to be demanding proof over promises following a jittery January. While health care sectors have shown some resilience, they haven’t provided a clear safe haven. The Dow dropped 0.58% on
24 January 2026
········
Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

New York, January 23, 2026, 15:50 (EST) — Regular session Shares of Boston Scientific Corp edged up roughly 1% to $92.20 in late afternoon trading on Friday, fluctuating earlier between $90.89 and $92.33. Investors are being nudged to watch pulsed-field ablation (PFA), a newer technique for treating atrial fibrillation—an irregular heartbeat linked to higher stroke risk. PFA delivers short electrical pulses to target faulty tissue, sparking a fierce battle for market dominance. This is critical now since the winners in PFA can outpace the broader medical-device market in growth, while the losers risk declines in procedure volumes and pricing. Boston
23 January 2026
····
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

New York, January 23, 2026, 05:29 EST — Premarket Novo Nordisk A/S (NVO) shares jumped 4.9% to $62.23 in premarket trading Friday following new data revealing a strong surge in U.S. prescriptions for its Wegovy weight-loss drug. The stock closed Thursday at $59.32. The numbers matter because investors now use weekly prescription data as a near-real-time indicator of demand for new obesity drugs, well ahead of quarterly sales reports. Novo is fighting to hold its ground in the GLP-1 drug space — medications that suppress appetite and regulate blood sugar — as competitors ramp up their efforts. The market, meanwhile,
23 January 2026
·····
UnitedHealth stock rises as CEO heads to Congress with Obamacare rebate pledge

UnitedHealth stock rises as CEO heads to Congress with Obamacare rebate pledge

New York, Jan 22, 2026, 11:27 (ET) — Regular session Shares of UnitedHealth Group Incorporated climbed 1.8%, closing at $353.85 on Thursday, up $6.10. The move came as investors digested the insurer’s pledge to rebate profits from its Obamacare segment amid renewed scrutiny from lawmakers. The company announced it will offer rebates to customers on its Affordable Care Act (ACA) marketplace plans in 2026, following the expiration of enhanced federal tax credits that had previously lowered premiums. Premiums are set to jump to an average of $1,904 in 2026, up from $888 in 2025, according to KFF, a health policy
22 January 2026
······
Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

New York, Jan 21, 2026, 13:17 EST — Regular session Shares of Abbott Laboratories ticked up 0.2% to $121.34 on Wednesday, trimming earlier volatility as traders braced for the company’s upcoming quarterly earnings report. Timing is key. Abbott is set to report before Thursday’s opening bell, as traders eye new guidance for 2026 following a flurry of device news over the past day. Abbott grabbed attention with news of fresh European clearance for an ablation catheter designed for heart-rhythm procedures, alongside a distinct partnership targeting a next-gen defibrillator implant. Abbott trailed behind despite healthcare’s overall strength: the Health Care Select
21 January 2026
·····
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

New York, Jan 20, 2026, 19:13 ET — After-hours Corvus Pharmaceuticals shares surged over threefold on Tuesday following fresh data release on its experimental eczema pill. The biotech also announced plans to raise $150 million through an underwritten stock offering. After-hours trading saw the stock surge roughly 167% to $21.41, with about 84 million shares changing hands. This move matters since Corvus is still in the clinical phase with no approved treatments. A clear placebo-controlled result can quickly shift biotech expectations—especially in atopic dermatitis, a crowded field where payers and doctors have alternatives. Corvus jumped on the rally with a
21 January 2026
·····
1 2 3 4 5 … 13

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop